The second act of a popular reprogramming factor could maximize the potential of iPSCs in research and regenerative medicine.
In a post on X on Tuesday, OpenAI CEO Sam Altman said that the company has trained a “new model” that’s “really good” at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback